US Patent

US10723730 — Solid forms of a selective CDK4/6 inhibitor

Composition of Matter · Assigned to Pfizer Inc · Expires 2034-02-08 · 8y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline forms of a specific chemical compound, a selective CDK4/6 inhibitor, used in treating cell proliferative diseases like cancer.

USPTO Abstract

This invention relates to the crystalline free base of acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, formula (1) having improved properties, to pharmaceutical compositions and dosage forms comprising the free base, and to methods for making and using such compounds, compositions and dosage forms in the treatment of cell proliferative diseases, such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US10723730
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-02-08
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.